Ntuziaka maka iji ọgwụ ọgwụ Trazhenta

Mbadamba ụrọ ọ bụla nwere fim nwere: ihe na-arụ ọrụ: linagliptin 5 mg,

ndị mbụ: mannitol, steepụ pregelatinized, copovidone, magnesium stearate, Opadray pink (02F34337) (hypromellose 2910, titanium dioxide (E171), talc, macrogol 6000, iron ironide (E172)).

Mbadamba ụrọ biconvex gbara agba nwere akụkụ gbara agba, kpuchie ya na fim nke agba uhie na-acha uhie uhie, na iji akara nke ụlọ ọrụ na-egosipụta ya n'otu akụkụ yana ihe osise "D5" n'akụkụ ọzọ nke mbadamba.

Omume ọgwụ

Linagliptin bụ onye na - egbochi enzyme dipeptidyl peptidase-4 (nke dị n'okpuru - DPP-4), nke a na - etinye aka na ntinye nke homonụ ndị dị na ya - glucagon-like peptide-1 (GLP-1) na glucose-based insulinotropic polypeptide (GIP). A na-ebibi homonụ ndị a ngwa ngwa site na DPP-4 nke enzyme. Ihe homonụ abụọ a na-etinye aka na nhazi usoro ọmụmụ nke glucose homeostasis. Okpukpo ukwu nke mmiri nzuzo n’ehihie di ala, ọ na adi elu n’iru nri. GLP-1 na GIP na - akwalite insulin biosynthesis na nzuzo ya site na pancreatic beta-ketki na ọkwa glucose ọbara dị elu ma dị elu. Na mgbakwunye, GLP-1 na-ebelata ihe nzuzo glucagon site na mkpụrụ ndụ alịcreatic, nke na-eduga n'ịbelata mmepụta glucose na imeju. Linagliptin (TRAGENT) na-arụ ọrụ nke ọma ma na-atụgharị uche ọzọ na DPP-4, nke na-ebute mmụba dị elu na ọkwa dị ogologo yana ịchekwa ọrụ ha ogologo oge. TRAGENTA na-eme ka mmiri ọgwụ glucose ghara ịdabere na glucose ma belata mmiri glucagon, na-ebute mmụba na glucose homeostasis. Linagliptin na-ejikọ na DPP-4 ahọrọ, na vitro nhọta ya karịrị nhọrọ maka DPP-8 ma ọ bụ ọrụ maka DPP-9 karịa ugboro 10,000.

Mlọ ọgwụ

Ntinye uche nke linagliptin na plasma na-ebelata usoro ato. Ogologo ndụ ọdụ ahụ dị ogologo, karịa 100 awa, nke bụ nke kachasị n'ihi nkwụsi ike nke linagliptin na enzyme DPP-4; nchịkọta ọgwụ adịghị eme. Ndụ ọkara na-arụ ọrụ, mgbe nchịkwa linagliptin ugboro ugboro na dose nke 5 mg, bụ ihe dị ka awa 12. N'ihe banyere ị linụ ọgwụ linagliptin na ọgwụ nke 5 mg otu ugboro n'ụbọchị, a na-enweta ọgwụ na -eme ka plasma kwụsie ike mgbe usoro nke atọ gasịrị. N'oge steeti pharmacokinetics (mgbe nchịkwa ọgwụ ahụ na a ọgwụ nke 5 mg), AUC (mpaghara n'okpuru oge ịta ahụhụ) nke plasma linagliptin mụbara site na 33% ma e jiri ya tụnyere usoro mbụ.

Ngwakọta nke onwe na ọnụọgụ nke ọdịiche dị n'etiti ndị ọrịa dị iche iche maka AUC nke linagliptin dị obere (12.6% na 28.5%, n'otu n'otu). Ihe ECC plasma nke linagliptin na-abawanye nwere mmụba dị obere. Aclọ ọgwụ ọgwụ nke linagliptin na ndị ọrụ afọ ofufo nwere ahụike na ndị ọrịa nwere ụdị ọrịa shuga mellitus 2 dị ka nke ahụ.

Ezigbo bioav adị nke linagliptin bụ ihe dịka 30%. Ceptionnabata nke linagliptin ya na nri nwere nnukwu abụba, mụbaa oge iji nweta ya_tah 2 awa na belata C_tah 15%, mana enweghị mmetụta na A11Co-72ch- Clinically pụtara mmetụta nke mgbanwe C_tah na T_tah anaghị atụ anya. Ya mere, enwere ike iji linagliptin mee nri ma n’agbanyeghi nri nri.

N'ihi ọgwụ mgbochi akwara, ọnụọgụ ọgwụ pụtara na nkesa ọgwụ n’akpa ọgwụ mgbe otu nlekọta intanetị linagliptin na-eji ọgwụ ruru 5 mg nye ihe dị mma bụ ihe dịka 1110 lita, nke na-egosi nkesa sara mbara n’akwara ahụ. Ijikọ lignagliptin na protein plasma na-adabere na ịta ọgwụ ma bụrụ ihe dịka 99% na ntinye nke 1 nmol / L, na mkpokọta> 30 nmol / L ọ na-agbadata na 75-89%, nke na-egosipụta ngụkọ nke njikọ ọgwụ ahụ na DPP-4 yana ịba ụba nke lignagliptin . N'elu nchịkọta dị elu, mgbe ngwụsị izu zuru oke nke DPP-4 pụtara, 70-80% nke linagliptin na-ejikọ na protein ndị ọzọ na plasma (kama DPP-4), na 30-20% nke ọgwụ ahụ nọ na plasma na ọnọdụ enweghị atụ.

Mgbe nchịkwa ọnụ nke akara 14C-linagliptin gosipụtara na ọnụọgụ 10 mg na mmamịrị, ihe dị ka 5% nke redioaktivu wepụtara. Akụkụ dị nta nke ọgwụ natara bụ metabolized. Achọpụtara otu metabolite bụ isi, ọrụ nke nke 13.3% nke nsonaazụ linagliptin na steeti ụlọ ọrụ ọgwụ, nke na-enweghị ọrụ ọgwụ yana emetụtaghị ọrụ inhibitory nke lignagliptin na plasma megide DPP-4.

4bọchị 4 mgbe nchịkwa 147 nke linagliptin nke akpọrọ n'ime isiokwu metụtara ahụike, ihe dị ka 85% nke ọgwụ a kapịrị (na feces 80% yana yana mmamịrị 5%). Nkwụghachi ụlọ na steetị steeti kwụ ọtọ bụ ihe dịka 70 ml / min.

Renrụ ọrụ na-arụ ọrụ na ụlọ

Iji tụọ ọgwụ pharmacookinetics nke linagliptin (na ọgwụ nke 5 mg) na ndị ọrịa nwere ogo dị iche iche nke ọdịda akụrụngwa na-adịghị ala ala ma e jiri ya tụnyere. Ndị na-ahụ maka ọmụmụ ike nwere usoro mmụta mepere emepe na iji usoro onwonye otutu. Ọmụmụ ihe ahụ gụnyere ndị ọrịa nwere akụrụ gbasara akụrụ, nke kewara dabere na nhichapụ nye nkuume (50 - 2).

Changesme mgbanwe iji dabere na okike ndi ọrịa adighi achoghi ya. Mmekọahụ enweghị mmetụta ọfụma n'ụlọ ọgwụ na ọgwụ ọgwụ nke linagliptin (dịka nsonaazụ nyocha nyocha nke ọgwụ nke ọnụ ọgụgụ ndị mmadụ mere na ndabere nke data sitere na ọmụmụ nke usoro na nke II.).

Ndozigharị ọnụọgụ dabere na afọ ndị ọrịa achọghị ya, ebe ọ bụ na afọ enweghị mmetụta ọfụma dị ukwuu na ọgwụ ọgwụ nke linagliptin. N'ime ndị ọrịa agadi (afọ 65-80, onye ọrịa kacha okenye. Ọ dị afọ iri asatọ na asatọ) na ndị ọrịa dị obere, e nwere ike ịhapụrụ plasma nke linagliptin.

Emebeghị nnyocha banyere ọgwụ ọgwụ nke lignagliptin na ụmụaka.

Ihe ngosi maka ojiji

A na-egosi TRAGENT maka ndị okenye okenye nwere ọrịa shuga nke ọrịa shuga 2 iji meziwanye njikwa glycemic: dị ka monotherapy

- maka ndị ọrịa na-enwe oke njide glycemic naanị site na nri ma ọ bụ mmega ahụ, yana maka ndị na - enweghị ike iwere metformin n'ihi ekweghị ekwe, ma ọ bụ na a machibidoro metformin n'ihe metụtara arụmọrụ ezughi oke.

- metformin, ọ bụrụ na nri na mmega ahụ yana metformin anaghị enye njikwa glycemic zuru oke,

- usoro nke sulfonylurea na metformin, ma ọ bụrụ na nri na mmega ahụ na usoro ọgwụgwọ ndị dị otu a anaghị enye njikwa glycemic zuru oke,

- insulin na ngwakọta na metformin ma ọ bụ na-enweghị ya, ma ọ bụrụ na nri na mmega ahụ ya na usoro ọgwụgwọ dị otú ahụ anaghị enye njikwa glycemic zuru oke.

Ime na lactation

A mụbeghị iji linagliptin n'ime ụmụ nwanyị dị ime.

Ihe omumu anum egosiputaghi ihe omuma nke nmebi omumu. Dịka ịkpachara anya, ekwesịrị ịgAGBARA TRIGENT n'oge afọ ime.

Ihe omuma enwetara na ihe omumu nke ogwu na anumanu na egosi ezi banyere linagliptin ma obu metabolites ya n’ime mmiri ara. Ihe ize ndụ nke ịmara ụmụ amụrụ ọhụrụ ma ọ bụ ụmụaka mgbe ha na-enye nwa ara.

Mkpebi ịkwụsị ị breastụ ara ma ọ bụ ị TRụ TRAG kwesịrị ịdabere na uru nke inye nwa ara yana ọgwụgwọ nne ya.

Emebeghị nnyocha banyere mmetụta nke TRAGENT na ọmụmụ ụmụ mmadụ. Ihe omumu omumu egosiputaghi ihe ojoo o gha eme.

Usoro onunu ogwu na nhazi

Usoro akwadoro bụ 5 mg ma ewere ya 1 oge kwa ụbọchị.

Na iji conformitant na metformin, dose nke metformin kwesịrị ịdị otu.

Mgbe ị na-ewere linagliptin na ngwakọta nke sulfonylurea ma ọ bụ insulin, ekwesịrị ị lowerụ mmiri nke sulfonylurea ma ọ bụ ọgwụ insulin iji belata ihe ize ndụ nke hypoglycemia.

Renrụ ọrụ na-arụ ọrụ na ụlọ

Ọchọghị ndị ọrịa nwere nsogbu nrụzi ọrụ gbasara akwara.

Ọrụ imeju na-arụ ọrụ

Ọmụmụ ọgwụ Pharmacokinetic na-egosi na achọrọ nhazigharị ọgwụ maka ndị ọrịa nwere ọrụ imeju na-arụ ọrụ, n’agbanyeghi, enweghị ahụmịhe banyere iji ọgwụ na ọgwụ na ndị ọrịa dị otú ahụ.

Ime mgbanwe iji dozie afọ ole achọrọ.

Agbanyeghị, ahụmịhe ụlọọgwụ na ndị ọrịa karịrị afọ iri asatọ nwere mmachi, ekwesịrị ịkpachapụrụ ndị otu a ọrịa anya.

Umuaka na umuaka

Emebeghi nchekwa na ịdị mma nke linagliptin maka ụmụaka na ndị na-eto eto.

Ọ bụrụ n ’ị aụ ọgwụ ole na ole, ọ ga-ebu ya ozugbo onye ọrịa chetara nke a. Ejila okpukpu abụọ n’ime otu ụbọchị.

Mmetụta akụkụ

A na-enyocha nchekwa nke TRAGENT na mkpokọta ndị ọrịa 6602 nwere ụdị ọrịa mellitus 2, gụnyere ndị ọrịa 5955 na-ewere ọgwụ 5 mg.

Mmụta ndị a na-ejikwa placebo gụnyere ọmụmụ ihe eji eme linagliptin dị ka ndị a:

n'ụdị monotherapy (obere oge, ruo izu 4)

dị ka monotherapy (oge> izu iri na abụọ) mgbakwunye metformin

mgbakwunye na ngwakọta nke metformin na sulfonylureas

mgbakwunye insulin na ngwakọta na ma ọ bụ na-enweghị metformin.

A na-egosipụta ugboro ole mmetụta ndị ọ na-arụ dị ka: oge ​​mgbe (> 1/10), ọtụtụ mgbe (site na> 1/100 ruo 1/1000 ruo 1/10000 ruo

Dodoụbiga ya ókè

N'oge ule a na-achịkwa n'ụlọ ọgwụ na-achịkwa ahụike, otu usoro ọgwụgwọ nke linagliptin, na-eru 600 mg (ugboro 120 a na-atụ aro ya), ka anabatacharịrị. Onweghi onye nwebeghi ahuma na usoro onunu ogwu kariri 600 mg.

N'ihe banyere oke ịdoụbiga mmanya ókè, ọ bụ ihe amamihe dị na ya iji usoro ndị ọzọ dị maka okike na-akwado ya, dịka ọmụmaatụ, iwepu ọgwụ a na-akwọpụghị akwara na eriri afọ, ileba anya na ọgwụgwọ dịka ọgwụgwọ egosi.

Mmekọrịta na ọgwụ ndị ọzọ

Na ntule mmekọrịta nyocha ọgwụ ọgwụ vitro

Linagliptin bụ onye na - adịghị ike asọmpi nke CYP3A4 isoenzyme, yana onye na - adịghị ike ma ọ bụ na - egbochi obere usoro nke ihe omume nke isoenzyme a. Linagliptin adịghị egbochi ndị ọzọ CYP icheenzymes ma ọ bụghị onye na-akụzi ha.

Linagliptin bụ mkpụrụ nke P-glycoprotein (P-gp) ma gbochie obere njem P-glycoprotein nke nwere usoro digoxin. Nyere data ndi a na nsonaazụ nke nkwukọrịta ọgwụ ọgwụ vivo, ike nke linagliptin soro ndị ọzọ mee ihe maka P-gp bụ ihe atụghị anya ya.

Na ntule mmekọrịta mkparịta ụka nke vivo

Mmetụta nke ọgwụ ndị ọzọ na linagliptin

Ihe omuma ogwu ndi a gosiputara obere ohere nke inwe nmekorita di egwu nke ogwu n’otu oge iji ogwu eme ihe.

Metformin: ojiji nke metformin ugboro ugboro na dose nke 850 mg ugboro 3 kwa ụbọchị na linagliptin na dose nke 10 mg 1 oge kwa ụbọchị emeghị ka mgbanwe mgbanwe dị ukwuu na ọgwụ ọgwụ nke linagliptin na ndị ọrụ afọ ofufo ahụike.

Nchịkọta ọgwụ nke Sulfonylurea: ọgwụ pharmokokinetics na ọnọdụ nke ịha nhata nke 5 mg nke linagliptin emetụtaghị site na iji otu ojiji nke 1.75 mg nke glibenclamide (glyburide).

Ritonavir: ojiji nke linagliptin (onunu ogwu nke 5 mg) na ritonavir (otutu onunu ogwu nke 200 mg), onye na - egbochi P-glycoprotein na isoenzyme CYP3A4, buliri AUC na C_tah linagliptin ihe dị ka ugboro 2 na ugboro atọ. Ntinye uche efu, nke a na-erughị 1% nke ọgwụgwọ ọgwụgwọ nke linagliptin, mụbara ugboro 4-5 mgbe ị na-emekọ ihe ọnụ na ritonavir. Ofkpụzi ihe ndọtị plasma nke linagliptin na steetibrium steeti pharmacokinetics na na enweghị ritonavir, gosipụtara na mmụba nke mkpughe ekwenyeghị na mmụba na mkpokọta lignagliptin. Mgbanwe ndị a dị na pharmacokinetics nke lignagliptin abụghị ihe dị mkpa banyere ọgwụ. Ya mere, mmekorita di egwu nke ulo ogwu na P-glycoprotein / SURZA4 inhibitors adighi acho.

Rifampicin: ojiji ugboro ugboro nke 5 mg nke linagliptin na rifampicin, onye na-arụ ọrụ nke P-gp na isoenzyme CYP3A4, mere ka ọnụ ahịa AUC na C kwụsịlata._tah lignagliptin site na 39.6% na 43.8%, n'otu n'otu, yana mbelata na mgbochi nke ọrụ basal nke dipeptidyl peptidase-4 ihe dịka 30%. Yabụ, ọgaghị adaba ọgwụgwọ linagliptin, nke ejikọtara ya na P-gp na-arụ ọrụ na-arụ ọrụ, enweghị ike ị nweta, ọkachasị n'iji njikọta ogologo oge. Ejighi iji ya mee ihe na ntinye aka ndi ozo nke P-gp na CYP3A4, dika carbamazepine, phenobarbital na phenytoin.

Nsonaazụ nke linagliptin na ọgwụ ndị ọzọ

Na omumu ihe omumu, dika egosiri n’okpuru, odighi uto nsogbu ogwu di na ogwu nke metformin, glyburide, simvastatin, warfarin, digoxin na onu ogwu, nke egosiputara na vivo, ma dabere na ikike di ala nke linagliptin banye n’ime nmekorita ogwu banyere ogwu nke iji dochie anya CYP3A4 , CYP2C9, CYP2C8, P-dr na ebufere motu nke cations Organic.

Metformin: ojiji nke linagliptin ugboro ugboro na mkpụrụ ọgwụ 10 mg otu ugboro n'ụbọchị yana 850 mg nke metformin, mkpụrụ nke mkpụrụ ọgwụ na - adịghị eduga n'ịgwọ ọgwụ dị egwu nke metformin na ndị ọrụ afọ ofufo ahụike. Yabụ na linagliptin abụghị ihe na - egbochi Uransportag • site na nkwupụta mkpụrụ ndụ.

Nchịkọta nke Sulfonylurea: ojiji nke 5 mg nke linagliptin na otu ọgwụ nke 1.75 mg nke glibenclamide (gliburide) mere ka mbelata na-adịghị akwụ ụgwọ na AUC na C_tah glibenclamide site na 14%. Ebe obu na glibenclamide bụ nke CYP2C9 metabolized, data ndị a na - egosikwa na linagliptin abụghị ihe na - egbochi CYP2C9. Enweghi mmekorita di egwu banyere ogwu na achoro uzo ozo (dika eg, glipizide, tolbutamide na glimepiride), dika, glibenclamide, ka otutu ihe dika CYP2C9.

Digoxin: ojiji nke ugboro 5 mg nke linagliptin na 0.25 mg nke digoxin emetụtaghị ọgwụ pharmokokinetics nke digoxin na ndị ọrụ afọ ofufo ahụike. Ya mere, na vivo linagliptin abụghị ihe na-egbochi ụgbọ njem mgbasa ozi P-glycoprotein.

Warfarin: linagliptin, etinyere ya ugboro ugboro na 5 mg kwa ụbọchị, agbanweghị ọgwụfokinetics nke S (-) ma ọ bụ R (+) warfarin, nke bụ mkpụrụ maka CYP2C9 ma na-achịkwa ya otu ugboro.

Simvastatin: linagliptin mgbe ndị ọrụ afọ ofufo dị mma na-ewere ya n'ọtụtụ usoro nwere mmetụta dị nta na ọgwụ ọgwụ nke simvastatin, mkpụrụ nwere mmetụta maka CYP3A4. Ke ama eben linagliptin ke usụ 10 mg (nke dị n’elu ọgwụgwọ) yana simvastatin na onodu 40 mg maka ụbọchị 6, AUC nke simvastatin na plasma ọbara mụbara site na 34%, na C_tah na plasma ọbara - pasent 10%.

Mgbochi ọgwụ a na-ekwu maka ya: ojiji nke linagliptin na ọgwụ nke 5 mg na levonorgestrel ma ọ bụ ethinyl estradiol agbanweghị ọgwụ ọgwụ nke ọgwụ ndị a.

Nchedo nchekwa

Ekwesighi iji ndị ọrịa nwere ụdị ọrịa shuga 1 nke mellitus ma ọ bụ maka ọgwụgwọ nke ketoacidosis nke ọrịa mamịrị.

Ọnọdụ nke hypoglycemia n'ihe banyere iji linagliptin dị ka monotherapy yiri nke placebo.

N'ime ọmụmụ ụlọ ọgwụ, a kọrọ na ihe kpatara hypoglycemia n'ihe banyere ojiji nke linagliptin na ọgwụ ndị a na-ekwenyeghị na ọ kpatara hypoglycemia (metformin, thiazolidinedione sitere n'ụdị ọgwụgwọ) yitere na nsonaazụ kwekọrọ na ya.

Mgbe ị na-ewere linagliptin na mgbakwunye na usoro sulfonylurea (yana usoro ọgwụgwọ metformin nke isi), ọnụ ọgụgụ nke ikpe hypoglycemia mụbara ma e jiri ya tụnyere otu placebo.

Ngwakọta nke sulfonylureas na insulin nwere ike ibute hypoglycemia. Ekwesịrị iji nlezianya kpoo Linagliptin yana usoro sulfonylurea na / ma ọ bụ insulin. Ọ bụrụ na ọ dị mkpa, ịbelata dose nke sulfonylurea ma ọ bụ ọgwụ insulin.

N'oge a na-ejikwa linagliptin na-azụ ahịa, a na-anata akụkọ maka oge mmepe nke nnukwu ọrịa ọrịa pancreatitis. Ekwesịrị ịgwa ndị ọrịa banyere njirimara njirimara nke nnukwu ọrịa ọrịa pancreatitis: afọ mgbu na-adịgide adịgide. A hụrụ nhugharị pancreatitis mgbe ọ kwụsịrị linagliptin. Ọ bụrụ na a na-enyo enyo na ọ na-enwe ọrịa pancreatitis, TRAG kwesịrị ịkwụsị.

Mwepụta wepụtara ya na ihe mejupụtara

A na-enweta trazenta n'ụdị mbadamba ihe eji eme ihe nkiri: biconvex, okirikiri, nwere ọnụ gbara agba, na-acha uhie uhie na agba, yana Mpempe akwụkwọ D5 dị n'otu akụkụ na akara nke ụlọ ọrụ na-emepụta ihe dị n'akụkụ nke ọzọ (pcs 7. Na blisters, na ngwugwu kaadi 2, 4 ma ọ bụ 8 blisters, pcs 10. Na blisters, na ngwungwu ngwugwu 3 blisters).

Nchikota kwa otu mbadamba 1:

• ihe na-arụ ọrụ: linagliptin - 5 mg,
• ihe inyeaka: stgelatinized starch, copovidone, ọka ọka, magnesium stearate, mannitol,
• n'ọbọ ihe nkiri: Opadray pink 02F34337 (titanium dioxide, macrogol 6000, talc, hypromellose, dye iron oxide red).

Usoro onunu ogwu na nhazi

A na-ewere ọnụ mbadamba nkume trazent. Theụ ọgwụ ahụ anaghị adabere n'oge iri nri, enwere ike ịme ya n'oge ọ bụla n'ụbọchị.

Usoro a tụrụ aro bụ 1 mbadamba (5 mg) otu ugboro n'ụbọchị.

Ọ bụrụ na echefula usoro nke ọzọ, onye ọrịa ahụ kwesịrị ị takeụ ọgwụ ozugbo ọ chetara mbadamba ihe furu efu. Kpoo ogwu a ma were mbadamba 2 n’otu oge ekwesighi.

Bụrụ na oruru imeju na / ma ọ bụ ọrụ akụrụ, yana n’ebe ndị ọrịa agadi nọ, ọchọghị imeghari dose.

Nsonaazụ

Nsonaazụ puru iche a na-ahụkarị na monotherapy na Trazent yana ọgwụgwọ njikọta na ndị ọrụ hypoglycemic ndị ọzọ:

• usoro nri: pancreatitis,
• usoro iku ume: ụkwara,
• dịghịzi usoro: hypersensitivity mmeghachi omume,
• ọrịa na-efe efe: nasopharyngitis.

Ọgwụ ndị a dị ka akụkụ nke usoro ọgwụgwọ mgbagwoju anya nwere ike ibute nsonaazụ ndị ọzọ dị otú a:

• pioglitazone, metformin na pioglitazone: hyperlipidemia na uru ibu,
• Ngwurugwu sulfonylurea: hypertriglyceridemia,
• insulin: afọ ntachi,
• Ngwurugwu sulfonylurea na metformin: hypoglycemia.

N’oge a na -echeta ihe banyere azụmaahịa, a chọpụtara ihe dị iche iche sitere na sistem na akụkụ ndị a:

• Usoro nri: ọgbụ nke akpụkpọ ahụ mucous nke onu uhere,
• dịghịzi usoro: urticaria, edere Quincke,
• anụ ahụ: ọkụ ọkụ.

Ntụziaka pụrụ iche

Mgbe ị na-eji ọgwụ ahụ Trazhenta n'otu oge na usoro ọgwụgwọ sulfonylurea, a ga-akpachara anya, ebe ọ bụ na nke ikpeazụ ahụ nwere ike ibute ọrịa hypoglycemia. Ọ bụrụ na ọ dị mkpa, ọ ga-ekwe omume belata ọgwụ ndị a na-enweta site na usoro sulfonylurea.

Trazhenta anaghị abawanye n'ihe ize ndụ nke ibute ọrịa na akwara.

Ọ bụrụ na a na-enyo nnukwu ọrịa pancreatitis, ekwesịrị ịkwụsị ọgwụ ahụ.

Emebeghị nnyocha pụrụ iche banyere mmetụta linagliptin na ike ịkwọ ụgbọala na ịrụ ọrụ nwere ike ịnwe ike. N'agbanyeghi nke a, n'ihi oke ụjọ nke akpịrị ọgbụgba, n'oge a na-eji ọgwụ ahụ, ị ​​kwesịrị ịkpachara anya mgbe ị na-eme ihe omume chọrọ mmụba nke nlebara anya na ọsọ nke mmeghachi omume psychomotor.

Mkparịta ụka ọgwụ ọjọọ

Site na iji ọgwụ ahụ trazhenta na metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin, rifampicin, ritonavir na ọgwụ mgbochi, ọgwụ ọgwụ, ọgwụ lignagliptin na ọgwụ ndị edepụtara agbanweghị ma ọ bụ agbanweghị nke ukwuu.

Ofzọ nke ngwa Trazenti na usoro onunu ogwu

A na -ekwu trazhenta ọnụ na ọgwụ akwadoro nke 5 mg (1 mbadamba) otu ugboro n'ụbọchị.

A na-ewere ngwá ọrụ ahụ n'oge ọ bụla n'ụbọchị, n'agbanyeghị nri ahụ, ọkacha mma ụbọchị niile n'otu oge. Ọ bụrụ na otu n'ime mbadamba nkume ndị ahụ, ị ​​ga-ewere ya n'oge ọ bụla ozugbo onye ọrịa chetara nke a, agbanyeghị, a gaghị atụ aro ka ị aụọ okpukpu abụọ n'otu ụbọchị.

Ozi ndi ozo

Ọgwụ ndị dị na usoro sulfonylureas, n'ọtụtụ oge, na-atụnye ụtụ na mmepe nke hypoglycemia. Ya mere, n'ọnọdụ ụfọdụ, ọ ga-ekwe omume belata ọgwụ ha mgbe ha na-ede akwụkwọ maka Trazhenta.

Maka ndị ọrịa nwere nnukwu nsogbu gbasara akụrụ, a na-atụ aro ọgwụ a ka ya na ọgwụ hypoglycemic ndị ọzọ.

Dabere na nyocha, Trazhenta na analogues na-ebelata oke mkpokọta haemoglobin glycosylated na glucose mgbe ị na-ewere mbadamba ibu ọnụ.

N'ihi ọgbụgba enwere ike ịdọ aka ná ntị, a na-adụ ọdụ ka anyị na-anya ụgbọ ala na igwe dị arọ n'oge ọgwụgwọ ọgwụ.

Ntụziaka maka Trazent na-egosi na ekwesịrị idobe mbadamba nkume na ọchịchịrị, akọrọ, dị jụụ ma ebe aka ụmụaka ruru.